Cipla Ltd, 4th floor, North Block, R&D Centre, Vikhroli (W), Mumbai - 400 083
India
Research Article
Assessment of Efficacy and Safety between Two Formulations of Formoterol Fumarate in Adolescents and Adults with Persistent Asthma
Author(s): Mahesh P, Joshi J, Rebello J, Purandare SM and Gogtay JAMahesh P, Joshi J, Rebello J, Purandare SM and Gogtay JA
Objective: The mandatory replacement of chlorofluorocarbons (CFCs) in pressurized metered dose inhalers (pMDIs) with non ozone depleting propellants such as hydrofluoroalkanes (HFA 134a) requires clinical testing that ensures the reformulated aerosol with HFA is as effective and well tolerated as the original CFC version. In view of this, a multicentre, randomised, parallel-group, double-blind study was conducted to compare the safety and efficacy of formoterol fumarate delivered by a MDI using the hydrofluoroalkane (HFA) 134a propellant (Cipla Ltd) with the CFC formulation (Foradil CFC pMDI, Novartis, UK) in adolescents and adults.
Methods: Patients on a stable dose of inhaled corticosteroids with a scope for improvement based on mean morning peak expiratory flow (PEF) and symptoms were randomised to receive formoterol HFA MDI 24 mg twice daily or formoterol CFC MDI 24 mg twi.. Read More»
DOI:
10.4172/2161-105X.1000278
Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report